BioSpace News Archive

Nurix Therapeutics, Inc. (Nasdaq: NRIX) today disclosed the discovery and structure of NX-1607 in the First Time Disclosures session at the American Chemical Society Spring 2024 meeting in New Orleans, LA.

SOPHiA GENETICS (Nasdaq: SOPH) today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.

Celularity Inc., a regenerative medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced that it has submitted a request to the U.S. Food and Drug Administration for orphan drug designation for its off-the-shelf, placental-derived cell therapy, PDA-002, for treating Facioscapulohumeral Muscular Dystrophy.

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- Inc. magazine recently revealed that Intelligencia AI , a provider of AI-powered decision-making solutions for the pharmaceutical industry, ranks No. 90 on the fourth annual Inc. 5000 Regionals: Northeast list , the most prestigious ranking of the fastest-growing Northeast private companies. Born of the annual Inc. 5000 franchise, this regional list represents a unique look at the most successful companies within the Northeast economy’s most

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its OSPREY clinical study, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation, has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.

Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”) today announced Memorial Sloan Kettering Cancer Center as lead clinical site for its NXC-201 relapsed/refractory AL Amyloidosis multi-site clinical trial.

FluoGuide A/S held its annual general meeting on 20 March 2024.

Bayer’s Pharmaceutical Division is set to embark on its next phase of growth, reshaping its executive Leadership Team to become more mission-centric and value focused.

Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today presented the discovery of SGR-1505, its MALT1 inhibitor, during the First Time Disclosure Session at the American Chemical Society (ACS) Spring 2024 Meeting.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.